Down-regulation of p57Kip2 induces prostate cancer in the mouse.

p57(Kip2) has been considered a candidate tumor suppressor gene because of its location in the genome, biochemical activities, and imprinting status. However, little is known about the role of p57(Kip2) in tumorigenesis and cancer progression. Here, we show that the expression of p57(Kip2) is significantly decreased in human prostate cancer, and the overexpression of p57(Kip2) in prostate cancer cells significantly suppressed cell proliferation and reduced invasive ability. In addition, overexpression of p57(Kip2) in LNCaP cells inhibited tumor formation in nude mice, resulting in well-differentiated squamous tumors rather than adenocarcinoma. Furthermore, the prostates of p57(Kip2) knockout mice developed prostatic intraepithelial neoplasia and adenocarcinoma. Remarkably, this mouse prostate cancer is pathologically identical to human prostate adenocarcinoma. Therefore, these results strongly suggest that p57(Kip2) is an important gene in prostate cancer tumorigenesis, and the p57(Kip2) pathway may be a potential target for prostate cancer prevention and therapy.

[1]  M. Oshimura,et al.  Suggestive evidence for chromosomal localization of non-coding RNA from imprinted LIT1 , 2007, Journal of Human Genetics.

[2]  M. Oshimura,et al.  Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer , 2004, Oncogene.

[3]  R. Matusik,et al.  Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[4]  G. Fan,et al.  Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. , 2006, Oral oncology.

[5]  B. Tycko,et al.  Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. , 1997, American journal of human genetics.

[6]  R. Peterson,et al.  Altered Prostatic Epithelial Proliferation and Apoptosis, Prostatic Development, and Serum Testosterone in Mice Lacking Cyclin-Dependent Kinase Inhibitors1 , 2005, Biology of reproduction.

[7]  K. Nakayama,et al.  Increased expression of vascular endothelial growth factor in placentas of p57Kip2 null embryos , 2002, FEBS letters.

[8]  T. Masaki,et al.  Expression of p57KIP2 in hepatocellular carcinoma: relationship between tumor differentiation and patient survival , 2002 .

[9]  A. Iavarone,et al.  E Proteins and Id2 Converge on p57Kip2 To Regulate Cell Cycle in Neural Cells , 2006, Molecular and Cellular Biology.

[10]  R. Dahiya,et al.  Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. , 1998, Differentiation; research in biological diversity.

[11]  S. Okret,et al.  p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. , 1999, Molecular endocrinology.

[12]  W. Gerald,et al.  Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors. , 1996, Cancer research.

[13]  S. Hayward,et al.  The rat prostatic epithelial cell line NRP‐152 can differentiate in vivo in response to its stromal environment , 1999, The Prostate.

[14]  N. Cho,et al.  Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma. , 1998, Gynecologic oncology.

[15]  R. Dahiya,et al.  A human prostatic epithelial model of hormonal carcinogenesis. , 2001, Cancer research.

[16]  R. Caprioli,et al.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.

[17]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[18]  T. Masaki,et al.  Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. , 2002, International journal of oncology.

[19]  K. Miyazono,et al.  Smad-mediated Transcription Is Required for Transforming Growth Factor-β1-induced p57Kip2 Proteolysis in Osteoblastic Cells* , 2001, The Journal of Biological Chemistry.

[20]  M. Monden,et al.  Expression of p57/Kip2 Protein in Hepatocellular Carcinoma , 2001, Oncology.

[21]  M. Leibovitch,et al.  p57Kip2 Stabilizes the MyoD Protein by Inhibiting Cyclin E-Cdk2 Kinase Activity in Growing Myoblasts , 1999, Molecular and Cellular Biology.

[22]  R. Millikan,et al.  P57 (KIP2) polymorphisms and breast cancer risk , 1999, Human Genetics.

[23]  Renjie Jin,et al.  The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. , 2003, Molecular endocrinology.

[24]  A. Miyauchi,et al.  Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. , 2002, International journal of molecular medicine.

[25]  R. Cardiff,et al.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Jong-Yeon Shin,et al.  Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer , 2000, Experimental & Molecular Medicine.

[27]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[28]  P. Yaswen,et al.  p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. , 1999, Cancer research.

[29]  K. Nan,et al.  Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[30]  Hui Yue,et al.  Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer. , 2003, World journal of gastroenterology.

[31]  K. Taira,et al.  Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter. , 2000, Human gene therapy.

[32]  M. Vazquez,et al.  Assessment of p57KIP2 Gene Mutation in Beckwith-Wiedemann Syndrome , 2001, Hormone Research in Paediatrics.

[33]  C. Cordon-Cardo,et al.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. , 1999, Journal of the National Cancer Institute.

[34]  J. Massagué,et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.

[35]  R. Matusik,et al.  NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice , 2004, Cancer Research.

[36]  M. Barbacid,et al.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. , 1997, Genes & development.

[37]  R. Chetty.  p27 Protein and Cancers of the Gastrointestinal Tract and Liver: An Overview , 2003, Journal of clinical gastroenterology.

[38]  R. DePinho,et al.  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[40]  Yun-Fai Chris Lau,et al.  Unopposed c‐MYC expression in benign prostatic epithelium causes a cancer phenotype , 2005, The Prostate.

[41]  A. Arnold,et al.  Cyclins and oncogenesis. , 1993, Biochimica et biophysica acta.

[42]  S. Elledge,et al.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. , 1995, Genes & development.

[43]  L. Reid,et al.  Genomic organization of the human p57KIP2 gene and its analysis in the G401 Wilms' tumor assay. , 1996, Cancer research.

[44]  M. Leibovitch,et al.  Stabilization of MyoD by Direct Binding to p57Kip2 * , 2000, The Journal of Biological Chemistry.

[45]  R. Weksberg,et al.  Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. , 2000, The American journal of pathology.